^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Selective serotonin reuptake inhibitor

    Related drugs:
    6d
    Acupuncture as a modulator of microglial polarization and pyroptosis in depression: evidence from a chronic unpredictable mild stress rat model. (PubMed, Metab Brain Dis)
    Acupuncture alleviates depression-like behaviors in CUMS-induced rats by modulating microglial polarization and inhibiting neuroinflammation-mediated pyroptosis. Our findings provide further evidence supporting acupuncture as a viable strategy for depression treatment.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • MRC1 (Mannose Receptor C-Type 1) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CASP1 (Caspase 1)
    |
    fluoxetine
    6d
    Repurposing the SSRI paroxetine increases lymphocyte mobilization and improves the efficacy of measles virus-based immunovirotherapy. (PubMed, Mol Ther Oncol)
    Furthermore, repurposing paroxetine, one of the Food and Drug Administration-approved selective serotonin reuptake inhibitors (SSRIs) with GRK-2 inhibitory action, enhanced this effect, leading to greater lymphocyte circulation, activation, and improved survival in an orthotopic syngeneic mouse model. By overcoming key mechanisms of immune suppression and repurposing a widely available, clinically safe drug, this strategy represents a highly translatable approach to enhancing the efficacy of immunovirotherapy for gliomas.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    7d
    Lux4UA: Building Ukraine's Strength in PTSD Treatment and Research (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, University of Luxembourg | Not yet recruiting --> Recruiting
    Enrollment open
    9d
    Hypersensitization of peripheral immune cells from major depressive disorder patients is mildly attenuated by fluoxetine in vitro. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry)
    In summary, fluoxetine has highly significant immunoregulatory effects in patients with MDD and not in controls. Unfortunately, these effects only partly attenuate the immune sensitization in MDD.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCL27 (C-C Motif Chemokine Ligand 27)
    |
    fluoxetine
    9d
    Efficacy and Safety of Probiotics for Anxiety Depression (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, Moon (Guangzhou) Biotechnology Co., Ltd.
    New trial
    14d
    Xianglian Pills ameliorate ulcerative colitis combined with depression in mice via histone demethylation (PubMed, Zhongguo Zhong Yao Za Zhi)
    Fifty male C57BL/6 mice were randomized into control, model, XLP(2.7, 5.4 mg·g~(-1)), and 5-aminosalicylic acid+fluoxetine groups...Furthermore, XLP lowered the levels of TNF-α, IL-1β, IL-6, and IL-23, down-regulated the transcript levels of IL-6 and IL-23α and the protein level of H3K4me3 while up-regulating the protein level of KDM5B in the cerebral cortical area and the colon tissue, and increased the binding of KDM5B to the IL-6 and IL-23α promoters. XLP may affect H3K4me3 demethylation through KDM5B to reduce the production of inflammatory factors and alleviate the inflammatory response, thus ameliorating UC combined with depression.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL23A (Interleukin 23 Subunit Alpha) • IL1B (Interleukin 1, beta) • KDM5B (Lysine Demethylase 5B)
    |
    fluoxetine
    14d
    A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD (clinicaltrials.gov)
    P4, N=302, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    14d
    CSA-HF: Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment (clinicaltrials.gov)
    P4, N=200, Not yet recruiting, VA Office of Research and Development | Initiation date: Jan 2026 --> Oct 2026
    Trial initiation date
    17d
    Lux4UA: Building Ukraine's Strength in PTSD Treatment and Research (clinicaltrials.gov)
    P=N/A, N=120, Not yet recruiting, University of Luxembourg
    New trial
    28d
    VENTURA-RWE: A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (clinicaltrials.gov)
    P=N/A, N=545, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    29d
    MD FluNCS: Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery (clinicaltrials.gov)
    P3, N=46, Not yet recruiting, Washington University School of Medicine | Initiation date: Oct 2025 --> Feb 2026
    Trial initiation date
    1m
    Fluvoxamine for Long COVID-19 (clinicaltrials.gov)
    P2/3, N=191, Completed, Washington University School of Medicine | Active, not recruiting --> Completed
    Trial completion